Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.

2017

Harrington, Karra D

Lim, Yen Ying

Ames, David

Hassenstab, Jason

Laws, Simon M

Martins, Ralph N

Rainey-Smith, Stephanie R

Robertson, Joanne

Rowe, Christopher C

Salvado, Olivier

Doré, Vincent

Villemagne, Victor L

Snyder, Peter J

Masters, Colin L

Maruff, Paul

Alzheimer disease

Amyloid

Cognitive aging

Memory

Normal aging

Journal Article

0000-0003-3910-2453

10.1016/j.dadm.2017.05.006

INTRODUCTION: High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. METHOD: Cognition was measured over 72 months and compared between low (Aβ-) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. RESULTS: Compared to the Aβ- group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. DISCUSSION: Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

link

Alzheimer's & dementia (Amsterdam, Netherlands) 2017; 8: 156-164

Alzheimer's & dementia (Amsterdam, Netherlands)

2352-8729